On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze), an insulin-like growth factor-1 receptor (IGF-1R) antagonist developed by Viridian Therapeutics, Inc., for the treatment of thyroid eye disease (TED) [1,2]. The approval covers TED regardless of disease activity or duration, making Lumvoa the first therapy in its class labeled from launch for both the active inflammatory phase and the chronic, “burned-out” phase of the disease [1,8]. The decision followed Breakthrough Therapy Designation and Priority Review, and was supported by two pivotal phase 3 trials, THRIVE and THRIVE-2 [1,11].
FDA Novel Drug Snapshot
Lumvoa
veligrotug-vvze
Drug Class
IGF-1R antagonist (monoclonal antibody)
Developer
Viridian Therapeutics, Inc.
Indication
Thyroid eye disease (TED) regardless of disease activity or duration — the first approved TED therapy labeled for both active and chronic stages
Administration Route
IV infusion — 5 doses, every 3 weeks, 12-week course
Pivotal Trials
THRIVE & THRIVE-2, phase 3
Regulatory Status by Region
Snapshot reflects publicly available regulatory status as of July 6, 2026, and may change as review timelines progress. Not a substitute for the full FDA prescribing information.
Also Known As
- Brand name: Lumvoa
- Generic/active ingredient name: veligrotug-vvze
- Development code name: VRDN-001
- Occasionally referenced in trade press simply as “veligrotug” (the brand name Lumvoa was assigned closer to approval, so earlier 2025–2026 coverage of the phase 3 program refers only to veligrotug or VRDN-001) [3,4]
- Common misspellings/variants to be aware of when searching: “Lumvoa,” “Lumvoa TED,” “veligrotug vvze,” “veligrotug-vvze”
Also Read: Tryptyr: A Breakthrough in Dry Eye Disease Treatment
Lumvoa Approved Indications
Lumvoa is indicated for the treatment of thyroid eye disease in adults, regardless of TED disease activity or duration [1,6]. This is a broader day-one label than most biologics receive in this space: the approval did not restrict use to patients within a defined window of symptom onset or a minimum clinical activity score, and instead drew on two separate pivotal trials — one enrolling patients with active, inflammatory TED and one enrolling patients with chronic, low-activity TED — to support use across the full disease spectrum [3,4,8]. TED itself is a rare autoimmune orbitopathy, most often arising in patients with Graves’ disease, in which immune-mediated inflammation and remodeling of orbital tissue produces proptosis (eye bulging), diplopia (double vision), pain, eyelid retraction, and, in severe cases, compressive optic neuropathy [6,8].
Mechanism of Action
Veligrotug-vvze is a full antagonist monoclonal antibody directed at the insulin-like growth factor-1 receptor (IGF-1R) [1,3]. In TED, IGF-1R is overexpressed on orbital fibroblasts — the connective-tissue cells behind and around the eye — and its signaling cross-talks with the thyroid-stimulating hormone receptor (TSHR) pathway implicated in Graves’-associated orbital inflammation [6,8]. By blocking IGF-1R autophosphorylation, veligrotug is designed to interrupt this signaling cascade and reduce the abnormal fibroblast activation that drives tissue expansion and inflammation, though the company and independent reviewers note that its precise mechanism of benefit in TED has not been fully characterized [6]. Veligrotug is described as a full antagonist, in contrast to the partial antagonism associated with the earlier-approved IGF-1R inhibitor in this class — a distinction that is mechanistically interesting but has not been evaluated in head-to-head trials [8,9].
Clinical Trial Data
The BLA was supported by two global, randomized, double-masked, placebo-controlled phase 3 trials [1,11]:
THRIVE (NCT05176639) enrolled 113 adults with moderate-to-severe active TED (onset within 15 months, proptosis ≥3 mm above baseline, Clinical Activity Score ≥3) across 29 sites in North America, Europe, and Australia. Patients were randomized 2:1 to veligrotug 10 mg/kg or placebo, given as 5 IV infusions every 3 weeks [3,7]. At the week-15 primary analysis, veligrotug produced a proptosis responder rate (PRR, ≥2 mm reduction by Hertel exophthalmometry) of roughly 70%, versus about 5% with placebo — a result the trial authors reported as statistically significant across every primary and secondary endpoint (all P<0.001) [3,7]. Diplopia improved in approximately 59% of veligrotug-treated patients with baseline diplopia, and around 49% achieved complete diplopia resolution, compared with 20% and 12%, respectively, on placebo [3,7]. Benefit was apparent early, with proptosis reductions observed by week 3, after a single infusion [3,7,9].
THRIVE-2 (NCT06021054) enrolled 188 adults with moderate-to-severe chronic TED (onset >15 months, mean time since onset approximately 70 months), randomized 2:1 to the same veligrotug regimen or placebo [4,9]. At week 15, the proptosis responder rate was approximately 56% with veligrotug versus 8% with placebo, the diplopia responder rate was roughly 56% versus 25% on placebo, and about 32% of treated patients achieved complete diplopia resolution versus 14% with placebo [4,9]. Trial investigators highlighted this as the first randomized phase 3 result to show statistically significant improvement in both proptosis and diplopia specifically in the chronic TED population, a group that has historically had few pharmacologic options once the active inflammatory window has passed [4,9].
Discontinuation related to adverse events was low in both trials: reported figures put THRIVE-2 completion at roughly 94% and THRIVE’s discontinuation rate at about 4% (i.e., ~96% completion) [4,9]. It is worth noting for readers evaluating the evidence base that, as of this writing, full peer-reviewed publication of THRIVE-2 data has appeared in a specialty-journal supplement, while independent commentators have flagged that some effect-size details were still being finalized in the peer-reviewed literature at the time of approval — a normal, if worth-flagging, lag between a company’s topline readout and full journal publication [8,9].
Safety and Warnings
The points below are drawn from the approved Lumvoa prescribing information and reporting on it; they are regulatory/label facts, not treatment guidance, and any decision about suitability for an individual patient rests with the prescribing physician [1,6].
- Hearing impairment, including hearing loss that may be permanent — a class-wide signal for IGF-1R inhibitors. The label requires a baseline hearing assessment before treatment, with further assessments during and after the infusion course [6,8].
- Hyperglycemia — reported in roughly 12% of patients in clinical trials, including patients without pre-existing diabetes; the label calls for glucose assessment before infusions and continued monitoring during treatment [6,8].
- Infusion reactions — occurring in approximately 9% of patients, generally mild-to-moderate (transient blood pressure changes, fever, chills, headache, fatigue), and typically managed with premedication or a slower infusion rate [6,8].
- Inflammatory bowel disease (IBD) exacerbation — a risk flagged for IGF-1R inhibitors as a class; the label calls for evaluation if IBD is suspected during treatment [6,8].
- Embryo-fetal risk — Lumvoa is not to be used in pregnancy. Patients of reproductive potential are advised to use effective contraception before starting treatment, throughout the course, and for 6 months after the final infusion, with a pregnancy test required before initiation [6].
- Common adverse reactions (≥5% incidence) reported in the pivotal trials include muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reactions, nausea, nasopharyngitis, elevated creatine phosphokinase, dry skin, and hypertension; menstrual disorders were reported in roughly 29% of menstruating women in the trials [6].
Dosing and Administration
(Label information only — the treating physician determines the appropriate regimen for an individual patient based on their clinical status.)
Lumvoa is supplied as a 500 mg/10 mL (50 mg/mL) single-dose vial for IV infusion and must not be given as an IV push, bolus, or concomitantly with other agents [6]. The labeled regimen is 10 mg/kg administered intravenously once every 3 weeks, for a total of 5 infusions over a 12-week course, with the first infusion given over roughly 30–45 minutes [5,6]. This is a materially shorter course than the standard-of-care comparator discussed below, which is a clinically relevant logistics fact for infusion-center scheduling and for patients weighing treatment burden [7,9].
India / Global Regulatory Status
As of July 6, 2026:
- United States (FDA): Approved June 26, 2026, with immediate commercial launch announced by Viridian [1].
- European Union (EMA): A Marketing Authorization Application was submitted in January 2026 and accepted for CHMP review in February 2026; no EMA decision had been announced as of this writing [10,17].
- India (CDSCO): No CDSCO filing or approval for veligrotug/Lumvoa was identified as of this writing. This is a “not yet available in India” flag rather than a confirmed timeline — Indian regulatory or commercial availability, if it comes, would be expected to follow well after the US and EU decisions, consistent with the typical sequencing for a newly approved specialty biologic [16].
Regulatory Timeline
Lumvoa (veligrotug-vvze) — Path to Approval
May 2025
Breakthrough Therapy Designation
FDA grants Breakthrough Therapy status based on phase 3 diplopia and proptosis data from the THRIVE and THRIVE-2 programs.
Dec 22, 2025
BLA Accepted & Priority Review Granted
FDA accepts the Biologics License Application and grants Priority Review, setting a PDUFA target action date of June 30, 2026.
Jan 2026
EMA Filing Submitted
Marketing Authorization Application for veligrotug submitted to the European Medicines Agency.
Feb 2026
EMA Accepts MAA for Review
CHMP review of the European filing formally begins.
Jun 26, 2026FDA Approval
Lumvoa Approved & Launched in the US
FDA approves veligrotug-vvze for thyroid eye disease regardless of activity or duration; Viridian begins immediate US commercial launch.
OngoingPending
EMA Decision (Europe)
CHMP review of the EU marketing authorization application is ongoing, with no decision date announced as of this writing.
Dates sourced from FDA and Viridian Therapeutics public disclosures. India/CDSCO filing status: not identified as of July 6, 2026 — no milestone shown pending confirmation.
On pricing: Viridian has not published a formal US list price in its approval announcement. Following the post-approval analyst call, at least one equity-research note reported that company management confirmed a per-course price near $450,000 for a 75 kg patient, positioned at approximate parity with the existing standard of care [15]. This figure comes from analyst commentary rather than an official wholesale acquisition cost (WAC) listing, so readers should treat it as directional rather than definitive. No India-specific or other-market pricing has been announced; if and when Lumvoa is filed and approved in India, pricing would be a separate, later disclosure.
Comparison to Existing Standard of Care: Lumvoa vs. Tepezza
Before Lumvoa, teprotumumab (Tepezza; originally developed by Horizon Therapeutics, now marketed by Amgen following Amgen’s October 2023 acquisition of Horizon) was the only FDA-approved medical therapy for TED, having first been approved in January 2020 for active disease and later expanded in 2023 to cover TED regardless of activity or duration [12,13,18]. The comparison below is descriptive, based on each product’s own labeling and public trial data; no head-to-head trial between veligrotug and teprotumumab has been conducted, so relative efficacy and safety cannot be determined directly [8,9].
| Lumvoa (veligrotug-vvze) | Tepezza (teprotumumab-trbw) | |
|---|---|---|
| IGF-1R antagonism | Full antagonist | Partial antagonist |
| Regimen | 10 mg/kg IV, 5 infusions, every 3 weeks (12-week course) | 10 mg/kg first infusion, 20 mg/kg thereafter, 8 infusions, every 3 weeks (~21-week course) |
| Labeled for chronic TED at initial approval | Yes, from day one | No — original 2020 approval covered active TED only; label expanded to include chronic/inactive disease in 2023 following a dedicated phase 4 trial [13] |
| Delivery format in current label | IV infusion only | IV infusion; a subcutaneous on-body-injector formulation reported positive phase 3 results in April 2026 but is not yet FDA-approved [14] |
| Key monitored risks | Hearing impairment, hyperglycemia, infusion reactions, IBD exacerbation | Hearing impairment, hyperglycemia, infusion reactions, IBD exacerbation — a substantially similar risk profile, per Lumvoa’s own label comparison [6] |
The most concrete, verifiable differentiators are the shorter infusion course (5 versus 8 infusions) and the breadth of the initial label (both TED stages from day one, versus a label that had to be expanded over time). Whether “full” versus “partial” IGF-1R antagonism translates into a meaningful clinical difference is not established by any published head-to-head data as of this writing [8,9].
Clinical Significance / What This Means
From a manufacturing quality and regulatory-affairs perspective, a few things about this approval are worth flagging beyond the headline efficacy numbers. First, running two separate, adequately powered phase 3 trials — one in active disease, one in chronic disease — to support a single, unrestricted label at first approval is a more resource-intensive development strategy than the “approve narrow, expand later” path Tepezza took, and it shows in the label breadth Viridian secured out of the gate [3,4,13]. Second, the safety profile disclosed at approval (hearing impairment, hyperglycemia, infusion reactions, IBD exacerbation) mirrors the known class effect for IGF-1R inhibitors rather than introducing a materially different risk signal — useful context for pharmacovigilance teams setting up post-marketing surveillance protocols, since the monitoring infrastructure many centers already built around Tepezza (baseline audiology, glucose checks, IBD screening) should transfer with minimal modification [6,8]. Third, the gap between the FDA action and the EMA’s ongoing review, and the apparent absence (as of this writing) of a CDSCO filing, is a reminder that “approved” is a jurisdiction-specific status — a detail that matters more in a specialty-biologic launch, where infusion-center logistics and payer coverage in each market take real time to stand up, than it does for oral generics [1,10,16,17].
It should also be stated plainly that the efficacy figures above come from a full approval based on adequately powered, randomized, placebo-controlled phase 3 data meeting pre-specified endpoints — not an accelerated approval on a surrogate marker — which is a meaningfully stronger evidentiary basis than some novel biologic approvals seen this year [2,3,4].
FAQ
Q-What is Lumvoa used for?
A-Lumvoa (veligrotug-vvze) is an IV biologic approved to treat thyroid eye disease (TED) in adults, regardless of how active the disease is or how long the patient has had it [1,6].
Q-Is Lumvoa the same as Tepezza?
A-No. Both are IGF-1R–targeted monoclonal antibodies used for TED, but they are different molecules from different companies, with different dosing regimens (5 infusions for Lumvoa versus 8 for Tepezza) and different regulatory histories. No study has directly compared the two head-to-head [6,12,13].
Q-How is Lumvoa given?
A-As an intravenous infusion administered by a healthcare professional, once every 3 weeks, for a total of 5 infusions over roughly 12 weeks, per the FDA label. The specific plan for any patient is set by their treating physician [5,6].
Q-What are the main risks to know about?
A-The label highlights hearing impairment (which may be permanent), hyperglycemia, infusion reactions, and a risk of inflammatory bowel disease exacerbation. Baseline hearing testing and blood glucose assessment are required before starting treatment [6].
Q-Is Lumvoa available in India?
A-Not as of this writing (July 6, 2026). No CDSCO filing or approval has been identified. It is currently an FDA-approved, US-launched product, with a European filing still under review [1,10,16].
Q-How much does Lumvoa cost?
A-Viridian has not published an official US list price. An analyst note following the approval reported a company-confirmed course price near $450,000 for a 75 kg patient, but this is not a formal WAC disclosure. No India or other-market pricing has been announced [15].
Q-What was the FDA approval based on?
A-Two phase 3 trials — THRIVE (active TED) and THRIVE-2 (chronic TED) — which the company reported met their primary and all secondary endpoints at the week-15 analysis [1,3,4].
References
- Viridian Therapeutics, Inc. Viridian Therapeutics announces U.S. FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease. News release. Published June 26, 2026. Accessed July 6, 2026.
- US Food and Drug Administration. Novel Drug Approvals for 2026. Accessed July 6, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- Yen MT, Cockerham K, Saeed P, et al; THRIVE study group. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. Published online June 1, 2026.
- Cockerham K, Tang R, Mandeville J, et al. THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks. Endocr Pract. 2025.
- Lumvoa (veligrotug-vvze) FDA approval history. Drugs.com. Accessed July 6, 2026.
- Lumvoa: uses, dosage, side effects, warnings. Drugs.com. Updated June 28, 2026. Accessed July 6, 2026.
- FDA approves veligrotug-vvze as first agent with data in both active and chronic thyroid eye disease. Pharmacy Times. 2026.
- FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages. Ophthalmology Times. 2026.
- Treatment for thyroid eye disease approved by FDA. AJMC. 2026.
- Viridian Therapeutics, Inc. Viridian Therapeutics reports first quarter 2026 financial results and highlights recent progress. News release. Published May 2026.
- Viridian Therapeutics, Inc. Viridian Therapeutics announces BLA acceptance and priority review for veligrotug for the treatment of thyroid eye disease. News release. Published December 22, 2025.
- Tepezza (teprotumumab-trbw) prescribing information. Original approval label, 2020, with subsequent supplements. accessdata.fda.gov.
- Tepezza (teprotumumab-trbw) FDA approval history. Drugs.com. Accessed July 6, 2026.
- Amgen announces positive topline phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease. News release. Amgen. Published April 6, 2026.
- Wedbush raises Viridian Therapeutics stock price target to $43. Investing.com. Published June 2026.
- Central Drugs Standard Control Organisation. List of Approved New Drugs. CDSCO, Government of India. Accessed July 6, 2026. https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/
- Viridian’s severe thyroid eye disease drug veligrotug among latest EU filings. Pink Sheet/Citeline. Published March 17, 2026.
- Amgen completes acquisition of Horizon Therapeutics plc. News release. Amgen. Published October 6, 2023.
